+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 183 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5165399
Description Jump to:
The global oncology companion diagnostic market size is expected to reach USD 8.2 billion by 2030, expanding at a CAGR of 12.9% from 2023 to 2030. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights

  • The product segment held the largest market share in 2022 owing to increased adoption and usage rate of CDx tests
  • A significant increase in the approval rate of CDx and a rise in investments for co-development of drugs and their CDx is expected to increase the revenue generation in the product segment
  • Consumables occupied a major share of the product segment owing to the frequent use and purchase of media, buffers, reagents, and other consumables required for CDx assay
  • Immunohistochemistry (IHC) occupied a major portion of the technology segment owing to the benefits offered by IHC technology including cost and time effectiveness, the suitability of the technique for small tumor types, high adoption of IHC for routine oncology CDx, and low technological requirements associated with IHC
  • Presence of a substantial number of FDA approved IHC based CDx assays such as EGFR pharmDx Kits, ER/PR pharmDx Kits, HercepTest Kits, PD-L1 IHC 28-8 pharmDx, VENTANA PD-L1 (SP142) Assay, VENTANA ALK (D5F3) CDx Assay, and VENTANA ALK IHC assay is also expected to increase revenue generation within the IHC segment
  • The Non-Small Cell Lung Cancer (NSCLC) segment dominated the market in 2022 and is expected to maintain its dominance during the forecast period
  • NSCLC is a lung cancer subtype that accounts for approximately 80% of all cases of lung cancer. According to data published by the American Cancer Society (ACS), in 2020, around 228, 820 new cases of lung cancer are projected to be diagnosed in the U.S.
  • The breast cancer and leukemia segments are expected to grow with substantial rates owing to a rise in the number of cancer cases
  • The hospital segment held the largest share in the market in 2022 and is expected to exhibit a considerable growth rate, owing to a rise in the number of cancer diagnostic tests in the hospitals
  • North America dominated the market in 2022 owing to the presence of a substantial number of players in this region, as well as the presence of a large number of FDA-approved CDx solutions in cancer therapeutics
  • Advancements in technologies and improvements in the economic condition are anticipated to drive the market at the fastest growth rate in the Asia Pacific
  • The presence of communities in Asian countries that are actively involved in monitoring and discovery of genetic biomarkers is expected to positively influence the market


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product & Service
1.1.2. Technology
1.1.3. Disease type
1.1.4. End use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product & service outlook
2.2.2. Technology outlook
2.2.3. Disease type outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Oncology Companion Diagnostic Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Oncology Companion Diagnostic: Product and Services estimates & Trend Analysis
4.1. Oncology Companion Diagnostic Market, By Product & Services Key Takeaways
4.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Product
4.3.1. Product and services market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Instrument
4.3.2.1. Instrument market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Consumable
4.3.3.1. Consumable market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Software
4.3.4.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Service
4.4.1. Service market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Oncology Companion Diagnostic: Technology Estimates & Trend Analysis
5.1. Oncology Companion Diagnostic Market, By Technology Key Takeaways
5.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Polymerase Chain Reaction (PCR)
5.3.1. Polymerase chain reaction (PCR) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Next-Generation Sequencing (NGS)
5.4.1. Next-generation sequencing (NGS) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immunohistochemistry (IHC)
5.5.1. Immunohistochemistry (IHC) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. In Situ Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH)
5.6.1. In itu Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Other Technologies
5.7.1. Other technologies market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Oncology Companion Diagnostic: By Disease Type Estimates & Trend Analysis
6.1. Oncology Companion Diagnostic Market, By Disease Type Key Takeaways
6.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Breast Cancer
6.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Non-Small Cell Lung Cancer
6.4.1. Non-small cell lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Colorectal Cancer
6.5.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Leukemia
6.6.1. Leukemia market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Melanoma
6.7.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Prostate Cancer
6.8.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.9. Others
6.9.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Oncology Companion Diagnostic: By End Use Estimates & Trend Analysis
7.1. Oncology Companion Diagnostic Market, By End Use Key Takeaways
7.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Hospital
7.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Pathology/Diagnostic Laboratory
7.4.1. Pathology/Diagnostic laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Academic Medical Center
7.5.1. Academic medical center market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Diagnostic Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Oncology Companion Diagnostic Market by Region: Key Takeaways
8.3. North America
8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Agilent Technologies, Inc.
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Illumina, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. QIAGEN N.V.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Thermo Fisher Scientific, Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. F. Hoffmann-La Roche Ltd.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. ARUP Laboratories
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Abbott
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Myriad Genetics, Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. bioMérieux SA
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Invivoscribe, Inc.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 3 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 4 North America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 5 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 6 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 7 U.S. oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 13 Canada oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 16 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 17 Europe oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 18 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 20 Germany oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 21 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 22 Germany oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 23 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 24 UK oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 25 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 26 UK oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 27 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 28 France oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 29 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 30 France oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 31 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 32 Italy oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 33 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 34 Italy oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 35 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 36 Spain oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 37 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 38 Spain oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 39 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 40 Denmark oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 41 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 42 Denmark oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 43 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 44 Sweden oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 45 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 46 Sweden oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 47 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 48 Norway oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 49 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 50 Norway oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 51 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 52 Asia Pacific oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 53 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 54 Asia Pacific oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 55 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 57 Japan oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 58 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 59 Japan oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 60 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 61 China oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 63 China oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 65 India oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 66 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 67 India oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 68 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 69 Australia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 70 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 71 Australia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 72 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 73 Thailand oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 74 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 75 Thailand oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 76 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 77 South Korea oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 78 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 79 South Korea oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 80 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 81 Latin America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 82 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 83 Latin America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 84 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 86 Brazil oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 87 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 88 Brazil oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 89 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 90 Mexico oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 91 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 92 Mexico oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 93 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 95 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 96 Argentina oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 97 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 98 Middle East and Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 99 Middle East and Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 100 Middle East and Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 101 Middle East and Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 102 Middle East and Africa oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 103 South Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 104 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 105 South Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 106 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 112 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 113 UAE oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 114 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 116 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 117 Kuwait oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 118 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Oncology companion diagnostic: Market outlook
Fig. 9 Oncology companion diagnostic: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Oncology companion diagnostic market driver impact
Fig. 15 Oncology companion diagnostic market restraint impact
Fig. 16 Oncology companion diagnostic market strategic initiatives analysis
Fig. 17 Oncology companion diagnostic market: Product & service movement analysis
Fig. 18 Oncology companion diagnostic market: Product & service outlook and key takeaways
Fig. 19 Product market estimates and forecasts, 2018 - 2030
Fig. 20 Service market estimates and forecasts, 2018 - 2030
Fig. 21 Oncology companion diagnostic market: Technology movement analysis
Fig. 22 Oncology companion diagnostic market: Technology outlook and key takeaways
Fig. 23 Polymerase chain reaction (PCR) market estimates and forecasts, 2018 - 2030
Fig. 24 Next-generation sequencing (NGS) market estimates and forecasts, 2018 - 2030
Fig. 25 Immunohistochemistry (IHC) market estimates and forecasts, 2018 - 2030
Fig. 26 In situ hybridization (ISH)/ fluorescence in situ hybridization (FISH) market estimates and forecasts, 2018 - 2030
Fig. 27 Other technologies market estimates and forecasts, 2018 - 2030
Fig. 28 Oncology companion diagnostic market: Disease type movement analysis
Fig. 29 Oncology companion diagnostic market: Disease type outlook and key takeaways
Fig. 30 Breast cancer market estimates and forecasts, 2018 - 2030
Fig. 31 Non-small cell lung cancer market estimates and forecasts, 2018 - 2030
Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
Fig. 33 Leukemia market estimates and forecasts, 2018 - 2030
Fig. 34 Melanoma market estimates and forecasts, 2018 - 2030
Fig. 35 Prostate cancer market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts, 2018 - 2030
Fig. 37 Oncology companion diagnostic market: End use movement analysis
Fig. 38 Oncology companion diagnostic market: End use outlook and key takeaways
Fig. 39 Hospital market estimates and forecasts, 2018 - 2030
Fig. 40 Pathology/Diagnostic laboratory market estimates and forecasts, 2018 - 2030
Fig. 41 Academic medical center market estimates and forecasts, 2018 - 2030
Fig. 42 Global oncology companion diagnostic market: Regional movement analysis
Fig. 43 Global oncology companion diagnostic market: Regional outlook and key takeaways
Fig. 44 North America market estimates and forecasts, 2018 - 2030
Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
Fig. 46 Canada market estimates and forecasts, 2018 - 2030
Fig. 47 Europe market estimates and forecasts, 2018 - 2030
Fig. 48 UK market estimates and forecasts, 2018 - 2030
Fig. 49 Germany market estimates and forecasts, 2018 - 2030
Fig. 50 France market estimates and forecasts, 2018 - 2030
Fig. 51 Italy market estimates and forecasts, 2018 - 2030
Fig. 52 Spain market estimates and forecasts, 2018 - 2030
Fig. 53 Denmark market estimates and forecasts, 2018 - 2030
Fig. 54 Sweden market estimates and forecasts, 2018 - 2030
Fig. 55 Norway market estimates and forecasts, 2018 - 2030
Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 57 Japan market estimates and forecasts, 2018 - 2030
Fig. 58 China market estimates and forecasts, 2018 - 2030
Fig. 59 India market estimates and forecasts, 2018 - 2030
Fig. 60 Australia market estimates and forecasts, 2018 - 2030
Fig. 61 Thailand market estimates and forecasts, 2018 - 2030
Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
Fig. 63 Latin America market estimates and forecasts, 2018 - 2030
Fig. 64 Brazil market estimates and forecasts, 2018 - 2030
Fig. 65 Mexico market estimates and forecasts, 2018 - 2030
Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
Fig. 67 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 70 UAE market estimates and forecasts, 2018 - 2030
Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • ARUP Laboratories
  • Abbott
  • Myriad Genetics, Inc.
  • bioMérieux SA
  • Invivoscribe, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.2 Billion
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Oncology Companion Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Oncology Companion Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 179 Pages
  • Global
From
Companion Diagnostics: Technologies and Markets - Product Image

Companion Diagnostics: Technologies and Markets

  • Report
  • 286 Pages
  • Global
From
Companion Diagnostics: Global Strategic Business Report - Product Image

Companion Diagnostics: Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027 - Product Image

Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027

  • Report
  • 546 Pages
  • Global
From
Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides - Product Image

Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides

  • Report
  • 541 Pages
  • Global
From

About the Companion Diagnostics Market

Oncology Companion Diagnostics (OCD) are a type of diagnostic test used to identify and monitor cancer patients. These tests are used to detect the presence of cancer, determine the type of cancer, and assess the patient's response to treatment. OCDs are used to identify genetic mutations that may be associated with the development of cancer, as well as to identify biomarkers that can be used to predict the risk of cancer recurrence. OCDs are also used to monitor the progression of cancer and to determine the effectiveness of treatment. OCD tests are typically performed in conjunction with other diagnostic tests, such as imaging and biopsy. They are used to provide a more comprehensive picture of the patient's cancer and to guide treatment decisions. Companies in the Oncology Companion Diagnostics market include Roche, Illumina, Thermo Fisher Scientific, Agilent Technologies, and Qiagen. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.